Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

The CXCR4 dim /CD5 bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations

Federico Pozzo, Gabriela Forestieri, Giulia Ianna, Filippo Vit, Erika Tissino, Tamara Bittolo, Lodovico Terzi Di Bergamo, Roberta Laureana, Agostino Tafuri, Annalisa Chiarenza, Francesco Di Raimondo, Jacopo Olivieri, Francesco Zaja, Luca Laurenti, Maria Ilaria Del Principe, Riccardo Bomben, Antonella Zucchetto, Davide Rossi, Valter Gattei

Blood (2022) 140 (Supplement 1): 4103–4104.

https://doi.org/10.1182/blood-2022-159947

Published: 2022

Journal Articles

The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis

Alfonso Piciocchi, Valentina Arena, Monica Messina, Sonia Maria Orlando, Raffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, Paola Fazi, Marco Vignetti, Francesco Buccisano, Adriano Venditti

Blood (2022) 140 (Supplement 1): 3192–3193.

https://doi.org/10.1182/blood-2022-158942

Published: 2022

Journal Articles

BCL-2 and BCL-X L Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study

Blood (2022) 140 (Supplement 1): 8979–8980.

https://doi.org/10.1182/blood-2022-163716

Published: 2022

Journal Articles

Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia

Raffaele Palmieri, Simona Iacobelli, Giovangiacinto Paterno, Moretti Federico, Elisa Buzzatti, Meddi Elisa, Savi Arianna, Gentiana Trotta, Flavia Mallegni, Maria Ilaria Del Principe, Luca Maurillo, Maria Teresa Voso, Adriano Venditti, Francesco Buccisano

Blood (2022) 140 (Supplement 1): 8961–8962.

https://doi.org/10.1182/blood-2022-159101

Published: 2022

Journal Articles

Clonal Evolution of Chronic Lymphocytic Leukemia with Bimodal CD49d Expression Reveals CD49d Plasticity

Blood (2022) 140 (Supplement 1): 9844–9846.

https://doi.org/10.1182/blood-2022-158904

Published: 2022

Journal Articles

An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment

Blood (2022) 140 (Supplement 1): 4111–4112.

https://doi.org/10.1182/blood-2022-159981

Published: 2022

Journal Articles

Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin

Chiara Cattaneo, Francesco Marchesi, Valentina Bonuomo, Nicola S Fracchiolla, Anna Candoni, Marianna Criscuolo, Lucia Prezioso, Crescenza Pasciolla, Maria Ilaria Del Principe, Michelina Dargenio, Giuseppe Tarantini, Maria Enza Mitra, Francesca Farina, Federica Colnaghi, Mariarita Sciumè, Gianpaolo Nadali, Alessandro Busca, Giuseppe Rossi, Livio Pagano

Blood (2021) 138 (Supplement 1): 4381.

https://doi.org/10.1182/blood-2021-149080

Published: 2021

Journal Articles

INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 4391.

https://doi.org/10.1182/blood-2021-149157

Published: 2021

Journal Articles

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Blood (2021) 138 (Supplement 1): 216.

https://doi.org/10.1182/blood-2021-150958

Published: 2021

Journal Articles

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Blood (2021) 138 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2021-147325

Published: 2021

Journal Articles

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2359.

https://doi.org/10.1182/blood-2021-147200

Published: 2021

Journal Articles

Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-139773

Published: 2020

Journal Articles

Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

Raffaele Palmieri, MD, Alfonso Piciocchi, Valentina Arena, MS, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Tiziana Ottone, Mariadomenica Divona, Serena Lavorgna, Maria Irno Consalvo, Consuelo Conti, Cristina Attrotto, Daniela Fraboni, Maria Teresa Voso, MD, William Arcese, MD PhD, Adriano Venditti, MD, Francesco Buccisano, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-139557

Published: 2020

Journal Articles

Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience

Raffaele Palmieri, MD, Giovangiacinto Paterno, Eleonora De Bellis, Elisa Buzzatti, Valentina Rossi, Ambra Di Veroli, MD, Fabiana Esposito, Lisa Mercante, Carmelo Gurnari, MD, Paola Casciani, Maria Ilaria Del Principe, Luca Maurillo, Maria Teresa Voso, MD, William Arcese, Adriano Venditti, Francesco Buccisano, MD

Blood (2019) 134 (Supplement_1): 2150.

https://doi.org/10.1182/blood-2019-127873

Published: 2019

Journal Articles

Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA)

Giovanni Del Poeta, MD, Annalisa Biagi, MD, Annalisa Chiarenza, MD PhD, Luca Laurenti, MD, Federico Pozzo, MSc, Idanna Innocenti, MD PhD, Riccardo Bomben, PhD, Maria Ilaria Del Principe, Enrico Santinelli, MD, Francesca Maria Rossi, PhD, Paolo de Fabritiis, MD, Maria Cantonetti, Antonella Zucchetto, William Arcese, Valter Gattei, MD

Blood (2019) 134 (Supplement_1): 1744.

https://doi.org/10.1182/blood-2019-122481

Published: 2019

Journal Articles

Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

Francesco Buccisano, MD, Raffaele Palmieri, MD, Maria Irno Consalvo, Alfonso Piciocchi, Luca Maurillo, Maria Ilaria Del Principe, Valentina Arena, Stefano Soddu, Ambra Di Veroli, MD, Giovangiacinto Paterno, Eleonora De Bellis, Daniela Fraboni, Consuelo Conti, Maria Teresa Voso, MD, William Arcese, Adriano Venditti

Blood (2019) 134 (Supplement_1): 2688.

https://doi.org/10.1182/blood-2019-128025

Published: 2019

Journal Articles

Early Intracranial Hemorrhages in Acute Promyelocytic Leukemia: Analysis of Neuroradiological and Clinico-Biological Parameters

Carmelo Gurnari, MD, Francesca Di Giuliano, Mariadomenica Divona, Alfonso Piciocchi, Laura Cicconi, Adriano Venditti, Maria Ilaria Del Principe, William Arcese, Francesco Lo-Coco, Francesco Garaci, MD, Maria Teresa Voso, MD

Blood (2019) 134 (Supplement_1): 5170.

https://doi.org/10.1182/blood-2019-125058

Published: 2019

Journal Articles

Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients

Blood (2019) 134 (Supplement_1): 5083.

https://doi.org/10.1182/blood-2019-129184

Published: 2019

Journal Articles

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Blood (2019) 134 (12): 935–945.

https://doi.org/10.1182/blood.2018886960

Published: 2019

Includes: Supplemental data

Journal Articles

Clinical Significance of Occult Central Nervous System Disease in Adult ACUTE Lymphoblastic Leukemia. a Multicenter,Report from the Campus ALL/Gimema Network

Blood (2018) 132 (Supplement 1): 658.

https://doi.org/10.1182/blood-2018-99-114177

Published: 2018

NARROW

The CXCR4 dim /CD5 bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations

The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis

BCL-2 and BCL-X L Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study

Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia

Clonal Evolution of Chronic Lymphocytic Leukemia with Bimodal CD49d Expression Reveals CD49d Plasticity

An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment

Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin

INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience

Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA)

Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

Early Intracranial Hemorrhages in Acute Promyelocytic Leukemia: Analysis of Neuroradiological and Clinico-Biological Parameters

Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Clinical Significance of Occult Central Nervous System Disease in Adult ACUTE Lymphoblastic Leukemia. a Multicenter,Report from the Campus ALL/Gimema Network

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only